Back to top

Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

Read MoreHide Full Article

Apellis Pharmaceuticals, Inc. (APLS - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $13.07 –$18.69 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Apellis Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. (ACOR - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is APLS going up? Or down? Predict to see what others think:Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Acorda Therapeutics, Inc. (ACOR) - free report >>

Apellis Pharmaceuticals, Inc. (APLS) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in